Literature DB >> 14973526

Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography.

E Kurtulan1, A Gulcu, M Secil, I Celebi, G Aslan, A A Esen.   

Abstract

The aim of this study was to investigate the effects of sildenafil on ocular hemodynamics by color Doppler ultrasonography (CDU). In all, 38 patients with erectile dysfunction diagnosed by International Index of Erectile Function (IIEF) and Sexual Health Inventory of Men (SHIM) scores were included into the study. After taking 100 mg of oral sildenafil citrate, all patients underwent CDU examination of central retinal artery at 60 and 75 min and CDU examination of cavernosal artery at 20, 60 and 75 min. All of the side effects during and after the test were also recorded. The mean cavernous artery peak systolic flow velocity increased significantly after sildenafil. However, no significant change was determined in central retinal artery flow parameters including peak systolic flow velocity, end-diastolic flow velocity, resistive index, pulsatility index, volume and diameter. Five patients experienced ocular side effects. No significant change was observed in retinal artery CDU measurements of patients having ocular side effects. Sildenafil has no effect on ocular hemodynamics on the basis of CDU. Ocular side effects may be the result of other changes in retinal photoreceptors rather than the ocular circulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973526     DOI: 10.1038/sj.ijir.3901189

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  6 in total

1.  Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension.

Authors:  Licia Matieli; Adriana Berezovsky; Solange Rios Salomão; Norma Allemann; Elisabeth Nogueira Martins; Flavio E Hirai; Jaquelina Ota-Arakaki; Maira S A Morales; Denise de Freitas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-19       Impact factor: 3.117

Review 2.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 3.  Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.

Authors:  Marilita M Moschos; Eirini Nitoda
Journal:  Drug Des Devel Ther       Date:  2016-10-19       Impact factor: 4.162

4.  Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States.

Authors:  Stephanie P Chen; Kuldev Singh; Shan C Lin
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

5.  Changes in Retinal and Choroidal Vascular Blood Flow after Oral Sildenafil: An Optical Coherence Tomography Angiography Study.

Authors:  David Berrones; Guillermo Salcedo-Villanueva; Virgilio Morales-Cantón; Raul Velez-Montoya
Journal:  J Ophthalmol       Date:  2017-10-09       Impact factor: 1.909

Review 6.  Visual Side Effects Linked to Sildenafil Consumption: An Update.

Authors:  Eva Ausó; Violeta Gómez-Vicente; Gema Esquiva
Journal:  Biomedicines       Date:  2021-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.